I congratulate the Fight Colorectal Cancer volunteers who took action this year to protect colorectal cancer research and prevention funding. We should be proud of our achievements, but we cannot become complacent. We must prepare for the Fiscal Year 2013 budget battle that lies ahead. Please register to attend Fight Colorectal Cancer’s Call-on Congress next March – where advocates from around the country will be urging their legislators to continue to protect colorectal cancer research funding.

The following are the spending outcomes on Fight Colorectal Cancer’s three appropriations priorities:

• The Colorectal Cancer Control Program (CRCCP)
• The National Cancer Institute (NCI) and
• The Peer Reviewed Cancer Research Program (PRCRP)

Note: The funding levels described below for the CRCCP and NCI do not reflect a 0.189 percent across-the-board cut that will be applied to all discretionary programs under the Departments of Labor, Health and Human Services (HHS), Education, with the exception of the Pell Grant Program.

Colorectal Cancer Control Program
Despite threats of deep spending cuts, the Centers for Disease Control and Prevention (CDC) received a slight increase, which allowed funding for the CRCCP to be preserved at its current level of $43.07 million. The CRCCP currently funds colorectal cancer programs in 25 states and four tribal organizations. Funded sites can use up to one-third of funds to provide no-cost screening services to eligible low-income men and women age 50-64. The remaining two-thirds of funds are for colorectal cancer education and outreach strategies. Maintaining CRCCP funding allows education and screening programs currently underway to continue. If funding for CRCCP was increased, education and screening programs could be expanded to more states.

National Institutes of Health

For FY2012, the NIH will receive a $299 million increase in its budget, with the various Institutes and Centers receiving
proportional increases, resulting in $5.082 billion for the NCI. The outcome reflects compromise between the $1 billion increase for the NIH in the House Labor-HHS -Education spending bill and the $190 million cut in the Senate bill. In addition to $30.698 billion for the NIH, the bill also includes $10 million for the Cures Acceleration Network (CAN), which was established under the Patient Protection and Affordable Care Act. The purpose of CAN is to accelerate the testing of high-need cures – drugs, biologics and devices – that are not attractive for development within the commercial market.

Peer Reviewed Cancer Research Program
Another important victory for the colorectal cancer community was the inclusion of $12.8 million for the Department of Defense’s (DoD) PRCRP. Comparatively, the PRCRP received $16 million for FY2011. While the program’s budget was decreased, some in Congress have called for the elimination of non-defense spending, including funding for medical research, from the DoD spending bill. The PRCRP funds research on several forms of cancer, including colorectal cancer.

Take action today, and tell Congress to increase fiscal year 2011 cancer research funding. As they head home for the election, take a minute to remind Members that they have work to finish when they come back to DC in November. Tell your Senators and Representative that you expect them to make colorectal cancer a top priority.

On Facebook? Take action and share this alert with your friends and family so that they can help in the fight too.

The Colorectal Cancer Coalition is working with Congressional leaders to increase fiscal year 2011 funding for the following colorectal cancer research and control programs:

• $50 million in funding for the Peer Reviewed Cancer Research Program (PRCRP) at the Department of Defense
• $35.2 billion for the National Institutes of Health (NIH)
• $5.79 billion for National Cancer Institute (NCI)
• $240 million for the National Center on Minority Health and Health Disparities (NCMHD)
• $601 million for Centers for Disease Control and Prevention (CDC) cancer programs
• $50 million for CDC’s National Comprehensive Cancer Control Program
• $50 million for CDC’s Colorectal Cancer Screening, Education & Outreach Initiative
• $65 million for CDC’s National Program of Cancer Registries
• $2.857 billion for the Food and Drug Administration (FDA)

Thanks to research, we have made great strides in the fight against colorectal cancer and treatment options have expanded to seven drugs. Today, people diagnosed with metastatic colorectal cancer are living longer than ever. But there is more work to be done, and we need continued federal funding of research programs to win the fight against colorectal cancer.

Take action today, and help us secure an increase in federal funding for fiscal year 2011.

Ms. Bauman thanked the Subcommittee members for including $15 million for the Department of Defense (DoD)’s Peer Reviewed Cancer Research Program (PRCRP) in the fiscal year 2010 bill and urged them to increase the level of funding for the PRCRP to $50 million in fiscal year 2011.

C3 is making the request for funding along with other advocacy groups representing the eight research areas in the PRCRP.  The program, funded through the DoD’s Congressionally Directed Medical Research Programs (CDMRP) supports high-quality cancer research, concentrating its resources on mechanisms which complement rather than duplicate the research approaches of the major funders of medical research in the United States.

The PRCRP also represents a unique partnership among the public, Congress, and the military.  Congress has required the DoD to ensure that the research funded through the program has relevance to service members and their families.  The research can help service members exposed to toxins and decrease the more than $1 billion that the DoD spends on cancer care.

Although the cancers included in this program are diverse, the research on these disease types is often synergistic. Advances or progress related to one cancer fuels the research on the other cancers in this program, and treatments initially approved for one cancer are routinely found to be effective in others.

In her testimony, Ms. Bauman advised the Subcommittee that areas of focus for colorectal cancer research in the PRCRP could be:

• An inexpensive, non-invasive, accurate screening test;
• Predictive markers to identify who will benefit from which treatments; and
• Accurate diagnostics that can evaluate the markers.

Discoveries resulting from investment in PRCRP research have the potential to transform the investigation of cancer, through the development of new prevention strategies and therapies, and someday, cures.  A $50 million investment will greatly enhance and accelerate such breakthroughs.  It is an opportunity to advance the best research to eradicate diseases and support the warfighter for the benefit of the American public.

Ms. Bauman’s complete testimony is available online here.

A list of the other witnesses who testified at the hearing is available here.